Genmab A/S (GMAB) ist ein börsennotiertes Unternehmen im Gesundheitswesen Sektor, tätig in der Biotechnologie Branche. Der Hauptsitz des Unternehmens ist in Copenhagen, Denmark. Der aktuelle CEO ist Jan van de Winkel.
GMAB hat IPO-Datum 2009-06-01, 2,638 Vollzeitbeschäftigte, gelistet an der NASDAQ Global Select, eine Marktkapitalisierung von $17.94B.
Genmab A/S is a Danish biopharmaceutical company founded in 1999 that develops antibody-based therapeutics for cancer and other serious diseases. The company's commercial portfolio includes DARZALEX (daratumumab) for multiple myeloma and other blood cancers, teprotumumab for thyroid eye disease, ofatumomab for chronic lymphocytic leukemia and multiple sclerosis, and amivantamab for gastric, esophageal, and lung cancers. Genmab maintains a robust pipeline of clinical and pre-clinical programs, including tisotumab vedotin for solid tumors, epcoritamab for lymphomas, and multiple early-stage candidates in Phase 2 development across oncology and other therapeutic areas. The company partners with leading pharmaceutical and biotech firms including Seagen, AbbVie, Janssen, BioNTech, and Novo Nordisk to advance its research and development efforts globally.
